Cure My Disease

Don't miss your cure!

 Log in / Sign up

New surgical tool aims to lower eye pressure in glaucoma patients

NCT ID NCT06615661

Disease control Sponsor: Iantrek, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study follows 100 adults with primary open-angle glaucoma who had a goniotomy procedure using the C-Rex surgical instrument. The goal is to see how well the surgery lowers intraocular pressure and reduces the need for glaucoma medications over 12 months. Researchers will also track any device-related complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
C-Rex Instrument, a manual ophthalmic surgical device used for goniotomy
What this could lead to
If successful, this could confirm that the C-Rex device is a safe and effective surgical option for lowering eye pressure in glaucoma patients.
What could go wrong
This is an observational study without a comparison group, so results may not prove the device is better than other treatments. Some patients may not achieve the desired pressure reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Aug 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible participants who underwent IOP-lowering surgical procedures using the C-Rex Instrument to perform ab-interno goniotomy

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primary open angle glaucoma * Goniotomy surgery performed using the C-Rex Instrument Exclusion Criteria: * History of intraocular surgery within 8 weeks prior to C-Rex surgery * Preoperative IOP higher than 33 mmHg * Presence of a glaucoma type other than POAG * Presence of clinically significant intraocular pathology other than cataract or glaucoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary open angle glaucoma (POAG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary open angle glaucoma (POAG)

Contacts and locations

Locations

  • CIRCLE Site 04

    Crossville, Tennessee, 38555, United States

  • CIRCLE Site 07

    Atlanta, Georgia, 30342, United States

  • CIRCLE Site 10

    DeLand, Florida, 32720, United States

  • CIRCLE Site 30

    Brentwood, New York, 11717, United States

  • CIRCLE Site 31

    Rockville Centre, New York, 11570, United States

  • CIRCLE Site 32

    Cape Coral, Florida, 33904, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.